Cumulative Subject Index Volumes 50-72 by George F. Vande Woude, George Klein

By George F. Vande Woude, George Klein

Educational Press proudly provides this Cumulative topic Index protecting Volumes 50-72 of Advances in melanoma learn. in a single entire resource, the reader can locate references to precise articles on themes similar to breast melanoma, prostate melanoma, Kaposi's sarcoma, Burkitt's lymphoma, leukemias, oncogenes, transcription components, tumor genetics, p53, T-cell receptors, and drug resistance. This cumulative index will serve not just as a whole assessment of the main themes released in Advances in melanoma study, but additionally as a trademark of the development made in melanoma learn over the past ten years.

Show description

Read Online or Download Cumulative Subject Index Volumes 50-72 PDF

Similar science (general) books

Advances in Taxation, Volume 16

"Advances in Taxation" publishes articles facing all points of taxation. Articles can deal with tax coverage concerns on the federal, country, neighborhood, or foreign point. The sequence basically publishes empirical experiences that tackle compliance, laptop utilization, schooling, criminal, making plans, or coverage matters.

Advances in 3D Geoinformation Systems (Lecture Notes in Geoinformation and Cartography)

This certain booklet makes a speciality of evaluating various kinds of 3D versions. as a result of the quick advancements in sensor recommendations an enormous quantity of 3D facts is out there. potent algorithms for (semi) automated item reconstruction are required. Integration of current 2nd items with top information is a non-trivial approach and wishes additional study.

Introduction to Marine Genomics

Marine biology has continuously performed a big function in organic learn, being on the foundation of many key advances. To a undeniable quantity, the impact of marine biology at the organic sciences used to be overshadowed over a interval of a number of years by way of the striking advances that have been made utilizing strong version organisms from terrestrial environments.

Extra info for Cumulative Subject Index Volumes 50-72

Sample text

5-56,60,62 Amino acid structure, VEGF, 67:284-286 6-Aminocaproic acid, plasminogen binding, 69:102 6-Aminolevulinic synthetase gene, c-erbA and, 59:104 Ammonium 2 1 tungsto-9-antimoniate, AIDS and, 51:347,356 Ammonium chloride, lysosomes and, 60: 284-285 Amphiregulin, transforming growth factor-a and, 58:28,37 Amphoterin, plasminogen binding, 69: 106 Amphotropic viruses development, from MuLV cancer resistant mice, 65: 177 effect of F v - 4 on, 65:190 Amplification, see Gene amplification Amplified DNA, evolution, 61:108-110 Amyloidosis, cutaneous lichen, with MEN IIA, 70:186-187 Anaphylaxis with desensitization reaction, Zilber and, 59:26-27 Anaplastic astrocytoma, oncogenesis of, 58: 124-125 8 Anatomy CpG islands in tumor suppressor genes, 72: 182-184 DNA methylation in higher-order eukaryotes, 72:147-150 Androgen receptor gene amplification in prostate cancer, 68: 247-248 mutations in prostate cancer metastasis, 68: 246 Androgens diet and, 51:63-64 endogenous growth inhibitors and, 57:436 mouse retrotransposons and, 56:231,240, 242 prostaticcancer and, 51:31-32 Anemia chromosome abnormalities and, 52:13 DHEA and, 51:418 protein tyrosine kinase GFRs and, 60: 52-53 refractory, see Refractory anemia Aneuploidy carcinogenesis and, role in cellular transformation, 65:2 1 chemical carcinogenesis and, 50:33 genomic instability and, 60:122,124, 135-136 p53 mutations and, 71:7-8 Angiogenesis in embryo chorioallantoic membrane, okadaic acid-induced, 61:164 FGF receptor multigene family and, 60: 2-3,35 fibroblast growth factors and, 59: 115-116,122,155 biological function, 59:140-142 tumors, 59:149,153-155 in human cancers, 67:266-267 and 1L-6 production, 66:ll inhibitors, 69:139-140,142 in vivo assays, 67:263-266 in Kaposi’s sarcoma, 53:83-84 normal cells, 69:135 occurrences, natural, 69:141 protein tyrosine kinase GFRs and, 6 0 5 0 regulation by VEGF-Flt receptors, 67: 28 1-282 role of SF, 67271-275 and scatter factor, 66:245 Subject Index separate from solid tumor development, 72: 18-19 therapeutic strategies using, 69160- 16 1 transforming growth factor-cu and, 58:47 tumor macrophage role, 6E269-270 PDGF role, 67:295-296 suppression, 67:309-310 tumor cells, 69:135-136,161-162 inducers, 69:142-149 inhibitor down-regulation, 69:149-156 mechanisms, 6 9 9 36- 137 phenotype, 69:139-141,156-159 subversion of normal physiological system, 69:141-142 Angiogenin, 69:144 Angioimmunoblastic lymphadenopathy, see Lymphadenopathy, angioimmunoblastic Angiolipoma, chromosomal aberrations, 69: 69-72 Angiopeptin, breast cancer therapy, 68:212 Angiostatin, 69:150,151 Angiotensin II,69:144 Animal models DNA methylation changes in cancer, 72: 175-1 76 lung carcinogenesis, p16 gene studies, 72: 162-163,187 Aniridia, Wilms’ tumor and, 59:47-50, 53-54,62 Ankyrin repeat domain, in IKB proteins, 66: 266-269 Antagonism, muscle cell regulation and, 58: 108-114 Antagonistic effects, cancer immunotherapy and, 59:262 Anthracyclins a-fetoprotein and, 56:280,287 lysosomes and, 60:284-285 multidrug resistance and, 52:170, 193 Antiandrogens, prostatic cancer and, 51:2 Antiangiogenic agents, 69160-161 Antibodies, see also Immunoglobulins; Monoclonal antibodies 4D5, HER-2/neu immunotherapy, 71:362 A .

5-56,60,62 Amino acid structure, VEGF, 67:284-286 6-Aminocaproic acid, plasminogen binding, 69:102 6-Aminolevulinic synthetase gene, c-erbA and, 59:104 Ammonium 2 1 tungsto-9-antimoniate, AIDS and, 51:347,356 Ammonium chloride, lysosomes and, 60: 284-285 Amphiregulin, transforming growth factor-a and, 58:28,37 Amphoterin, plasminogen binding, 69: 106 Amphotropic viruses development, from MuLV cancer resistant mice, 65: 177 effect of F v - 4 on, 65:190 Amplification, see Gene amplification Amplified DNA, evolution, 61:108-110 Amyloidosis, cutaneous lichen, with MEN IIA, 70:186-187 Anaphylaxis with desensitization reaction, Zilber and, 59:26-27 Anaplastic astrocytoma, oncogenesis of, 58: 124-125 8 Anatomy CpG islands in tumor suppressor genes, 72: 182-184 DNA methylation in higher-order eukaryotes, 72:147-150 Androgen receptor gene amplification in prostate cancer, 68: 247-248 mutations in prostate cancer metastasis, 68: 246 Androgens diet and, 51:63-64 endogenous growth inhibitors and, 57:436 mouse retrotransposons and, 56:231,240, 242 prostaticcancer and, 51:31-32 Anemia chromosome abnormalities and, 52:13 DHEA and, 51:418 protein tyrosine kinase GFRs and, 60: 52-53 refractory, see Refractory anemia Aneuploidy carcinogenesis and, role in cellular transformation, 65:2 1 chemical carcinogenesis and, 50:33 genomic instability and, 60:122,124, 135-136 p53 mutations and, 71:7-8 Angiogenesis in embryo chorioallantoic membrane, okadaic acid-induced, 61:164 FGF receptor multigene family and, 60: 2-3,35 fibroblast growth factors and, 59: 115-116,122,155 biological function, 59:140-142 tumors, 59:149,153-155 in human cancers, 67:266-267 and 1L-6 production, 66:ll inhibitors, 69:139-140,142 in vivo assays, 67:263-266 in Kaposi’s sarcoma, 53:83-84 normal cells, 69:135 occurrences, natural, 69:141 protein tyrosine kinase GFRs and, 6 0 5 0 regulation by VEGF-Flt receptors, 67: 28 1-282 role of SF, 67271-275 and scatter factor, 66:245 Subject Index separate from solid tumor development, 72: 18-19 therapeutic strategies using, 69160- 16 1 transforming growth factor-cu and, 58:47 tumor macrophage role, 6E269-270 PDGF role, 67:295-296 suppression, 67:309-310 tumor cells, 69:135-136,161-162 inducers, 69:142-149 inhibitor down-regulation, 69:149-156 mechanisms, 6 9 9 36- 137 phenotype, 69:139-141,156-159 subversion of normal physiological system, 69:141-142 Angiogenin, 69:144 Angioimmunoblastic lymphadenopathy, see Lymphadenopathy, angioimmunoblastic Angiolipoma, chromosomal aberrations, 69: 69-72 Angiopeptin, breast cancer therapy, 68:212 Angiostatin, 69:150,151 Angiotensin II,69:144 Animal models DNA methylation changes in cancer, 72: 175-1 76 lung carcinogenesis, p16 gene studies, 72: 162-163,187 Aniridia, Wilms’ tumor and, 59:47-50, 53-54,62 Ankyrin repeat domain, in IKB proteins, 66: 266-269 Antagonism, muscle cell regulation and, 58: 108-114 Antagonistic effects, cancer immunotherapy and, 59:262 Anthracyclins a-fetoprotein and, 56:280,287 lysosomes and, 60:284-285 multidrug resistance and, 52:170, 193 Antiandrogens, prostatic cancer and, 51:2 Antiangiogenic agents, 69160-161 Antibodies, see also Immunoglobulins; Monoclonal antibodies 4D5, HER-2/neu immunotherapy, 71:362 A .

5-56,60,62 Amino acid structure, VEGF, 67:284-286 6-Aminocaproic acid, plasminogen binding, 69:102 6-Aminolevulinic synthetase gene, c-erbA and, 59:104 Ammonium 2 1 tungsto-9-antimoniate, AIDS and, 51:347,356 Ammonium chloride, lysosomes and, 60: 284-285 Amphiregulin, transforming growth factor-a and, 58:28,37 Amphoterin, plasminogen binding, 69: 106 Amphotropic viruses development, from MuLV cancer resistant mice, 65: 177 effect of F v - 4 on, 65:190 Amplification, see Gene amplification Amplified DNA, evolution, 61:108-110 Amyloidosis, cutaneous lichen, with MEN IIA, 70:186-187 Anaphylaxis with desensitization reaction, Zilber and, 59:26-27 Anaplastic astrocytoma, oncogenesis of, 58: 124-125 8 Anatomy CpG islands in tumor suppressor genes, 72: 182-184 DNA methylation in higher-order eukaryotes, 72:147-150 Androgen receptor gene amplification in prostate cancer, 68: 247-248 mutations in prostate cancer metastasis, 68: 246 Androgens diet and, 51:63-64 endogenous growth inhibitors and, 57:436 mouse retrotransposons and, 56:231,240, 242 prostaticcancer and, 51:31-32 Anemia chromosome abnormalities and, 52:13 DHEA and, 51:418 protein tyrosine kinase GFRs and, 60: 52-53 refractory, see Refractory anemia Aneuploidy carcinogenesis and, role in cellular transformation, 65:2 1 chemical carcinogenesis and, 50:33 genomic instability and, 60:122,124, 135-136 p53 mutations and, 71:7-8 Angiogenesis in embryo chorioallantoic membrane, okadaic acid-induced, 61:164 FGF receptor multigene family and, 60: 2-3,35 fibroblast growth factors and, 59: 115-116,122,155 biological function, 59:140-142 tumors, 59:149,153-155 in human cancers, 67:266-267 and 1L-6 production, 66:ll inhibitors, 69:139-140,142 in vivo assays, 67:263-266 in Kaposi’s sarcoma, 53:83-84 normal cells, 69:135 occurrences, natural, 69:141 protein tyrosine kinase GFRs and, 6 0 5 0 regulation by VEGF-Flt receptors, 67: 28 1-282 role of SF, 67271-275 and scatter factor, 66:245 Subject Index separate from solid tumor development, 72: 18-19 therapeutic strategies using, 69160- 16 1 transforming growth factor-cu and, 58:47 tumor macrophage role, 6E269-270 PDGF role, 67:295-296 suppression, 67:309-310 tumor cells, 69:135-136,161-162 inducers, 69:142-149 inhibitor down-regulation, 69:149-156 mechanisms, 6 9 9 36- 137 phenotype, 69:139-141,156-159 subversion of normal physiological system, 69:141-142 Angiogenin, 69:144 Angioimmunoblastic lymphadenopathy, see Lymphadenopathy, angioimmunoblastic Angiolipoma, chromosomal aberrations, 69: 69-72 Angiopeptin, breast cancer therapy, 68:212 Angiostatin, 69:150,151 Angiotensin II,69:144 Animal models DNA methylation changes in cancer, 72: 175-1 76 lung carcinogenesis, p16 gene studies, 72: 162-163,187 Aniridia, Wilms’ tumor and, 59:47-50, 53-54,62 Ankyrin repeat domain, in IKB proteins, 66: 266-269 Antagonism, muscle cell regulation and, 58: 108-114 Antagonistic effects, cancer immunotherapy and, 59:262 Anthracyclins a-fetoprotein and, 56:280,287 lysosomes and, 60:284-285 multidrug resistance and, 52:170, 193 Antiandrogens, prostatic cancer and, 51:2 Antiangiogenic agents, 69160-161 Antibodies, see also Immunoglobulins; Monoclonal antibodies 4D5, HER-2/neu immunotherapy, 71:362 A .

Download PDF sample

Rated 4.16 of 5 – based on 28 votes